CERENOME, INC.
No enriched coverage for $PSTV in the last 7 days.
No SEC Form 4 filings for $PSTV in the last 30 days.
See all $PSTV insider activity →CERENOME, INC. (PSTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, August 14, 2026 – Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted th
Plus Therapeutics, Inc. (Nasdaq: PSTV) said its corporate rebrand to Cerenome will be completed on Aug. 3, 2026. The company will begin trading on Nasdaq under ticker CNSY. Cerenome plans an integrated CNS oncology approach combining its CNSide CSF diagnostics, investigational radiotherapeutic REYOBIQ, and proprietary data and AI platform.
Plus Therapeutics (Nasdaq: PSTV) said updated NCCN CNS cancer guidelines continue to support CSF analysis for leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients on intrathecal therapy. The company links the update to its CNSide CSF assay, citing FORESEE data of more than double tumor-detection sensitivity vs cytology and reporting 126M covered lives and 1,250 tests targeted for 2026.
Recent PSTV coverage spans financial news, corporate actions and earnings.
The 8-K provides fresh operating-loss and cash figures plus updated clinical and commercial execution milestones, shaping near-term risk and funding expectations.
Ticker/name change can drive short-term trading friction and liquidity effects, but it is not a fundamental operating update.
Guideline reinforcement and cited FORESEE sensitivity data support the commercial narrative for CNSide, but the release does not provide new regulatory or reimbursement approvals beyond what is already described.
ATM equity distribution can pressure near-term valuation/dilution expectations, but provides flexible funding for working capital.
CAP accreditation can improve reimbursement discussions and health-system adoption for the CNSide CSF assay, potentially accelerating commercial uptake.
alphai scores every news story that mentions PSTV with an AI model for sentiment and relevance, and aggregates insider trades from CERENOME, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CERENOME, INC. (PSTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, August 14, 2026 – Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted th
6 min readPlus Therapeutics, Inc. (Nasdaq: PSTV) said its corporate rebrand to Cerenome will be completed on Aug. 3, 2026. The company will begin trading on Nasdaq under ticker CNSY. Cerenome plans an integrated CNS oncology approach combining its CNSide CSF diagnostics, investigational radiotherapeutic REYOBIQ, and proprietary data and AI platform.
3 min readPlus Therapeutics (Nasdaq: PSTV) said updated NCCN CNS cancer guidelines continue to support CSF analysis for leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients on intrathecal therapy. The company links the update to its CNSide CSF assay, citing FORESEE data of more than double tumor-detection sensitivity vs cytology and reporting 126M covered lives and 1,250 tests targeted for 2026.
3 min readPLUS THERAPEUTICS, INC. (PSTV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001095981 0001095981 2026-06-01 2026-06-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2
2 min readPlus Therapeutics (NASDAQ:PSTV) said its CNSide Diagnostics unit received College of American Pathologists (CAP) accreditation for its CNSide CSF assay platform. The Houston lab passed an on-site CAP inspection covering protocols, documentation, quality control, staff, equipment, and management. The company said accreditation may support payer coverage, reimbursement talks, and faster commercial expansion; shares rose 8.7% to $5.89.
4 min readDespite a 4.80% decline in its stock price, Plus Therapeutics (PSTV) announced a significant milestone: its CNSide diagnostic system has secured a dedicated AMA billing code (0640U), effective July 1, 2026. This proprietary code will streamline reimbursement processes for the cerebrospinal fluid tumor cell diagnostic, enhancing its commercial infrastructure and market penetration in CNS oncology. The CNSide platform helps identify malignant cells in CSF, addressing a critical need in treating metastatic central nervous system malignancies.
3 min readPlus Therapeutics, Inc. announced the granting of inducement awards to two new employees. These awards, consisting of stock options and restricted stock units, were issued under the Company's 2015 New Employee Incentive Plan and approved by the Compensation Committee as required by Nasdaq Rule 5635(c)(4) to entice new talent. The awards vest over several years, contingent on continued employment.
2 min readPlus Therapeutics, Inc. (NASDAQ:PSTV) has appointed Ron Andrews to its Board of Directors, bringing over 35 years of experience in the diagnostics industry. Andrews has a strong background in capital raising and exits, having served in leadership roles at Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher. This appointment comes as the company faces financial challenges, with its stock having declined significantly over the past year, though InvestingPro analysis suggests it is slightly undervalued.
3 min readPlus Therapeutics (PSTV) is anticipated to report a year-over-year increase in earnings on higher revenues for the quarter ended March 2025, with an expected net loss of $0.17 per share. Despite a positive revision in the consensus EPS estimate over the last 30 days, the company has a negative Earnings ESP of -45.46%, suggesting analysts have turned bearish. Given its Zacks Rank #2, the combination of these factors makes it difficult to conclusively predict an earnings beat.
3 min readHOUSTON, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Plus Therapeutics, Inc. ( Nasdaq: PSTV ) ( the "Company" ) , a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system ( CNS ) cancers, announced it has completed a Type B meeting ...
3 min read
